Please login to the form below

Not currently logged in
Email:
Password:

Chugai appoints US CMO

Athos Gianella-Borradori has clinical experience at Novartis and Merck Serono

Japanese company Chugai Pharma has named Dr Athos Gianella-Borradori as chief medical officer of its US subsidiary.

Dr Gianella-Borradori was most recently chief medical officer at Norwegian firm Clavis Pharma having joined the company in 2010 from Merck Serono.

At Merck Serono he served as head of clinical development for small molecules in onco-haematology and his prior experience includes clinical roles across Europe at Novartis, Crucell, Bavarian Nordic and Cyclacel.

The appointment at Chugai Pharma marks Dr Gianella-Borradori's first US role. As chief medical officer he has responsibility for all clinical activity in the US and will participate in a leadership role on scientific and translational committees for its Tokyo-headquartered parent company.

He will also represent Chugai, in which Swiss pharma company Roche owns a majority stake, in its relationships with the US FDA, academia, clinical investigators and patient communities.

30th April 2014

From: Research

Share

Tags

Subscribe to our email news alerts

PMHub

Add my company
Evoke Kyne

Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...

Latest intelligence

The evolving healthcare advertising landscape
Industry experts share their insights on the emerging trends in healthcare advertising...
Clinical trial considerations: Why supporting HCPs matters...
When HCPs have the necessary information, they can more easily communicate it to patients using simplified language and a confident, calm tone....
Six ways to provide successful e-learning programs to healthcare professionals
Practical tips to setting up high-impact e-learning programs...